FDA puts Atara’s INDs on hold after rejection; Ascletis’ safety data for obesity pill

Plus, news about Amy­lyx and Sanofi:

FDA places hold on Atara Bio­ther­a­peu­tics’ ac­tive INDs: The holds af­fect the T cell ther­a­py that the agency re­ject­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.